Jayne Gurtler, MD
Hematology & Oncology · Metairie, LANPI 1396712808
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,189 of the $2,783 with a category attached, or 78.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 93 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$391
- Johnson & Johnson$376
- Amgen$252
- Novartis$239
- Astellas Pharma US Inc$218
- E.r. Squibb & Sons, L.L.C.$136
- plus $1K from 23 others
Across 37 payments — averaging $11,796 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$364K
- EMD Serono, Inc.$73K
What the payments were for
- Food & beverage$2,18979%
- Education$59421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $391 |
| Johnson & Johnson | 4 | $376 |
| Amgen | 2 | $252 |
| Novartis | 10 | $239 |
| Astellas Pharma US Inc | 6 | $218 |
| E.r. Squibb & Sons, L.L.C. | 2 | $136 |
| Array Biopharma Inc | 5 | $117 |
| AbbVie | 5 | $114 |
| Bayer | 5 | $112 |
| AstraZeneca | 1 | $110 |
| Sobi, Inc | 1 | $100 |
| Merck | 6 | $96 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Bristol Myers Squibb | 3 | $67 |
| CTI Biopharma Corp. | 2 | $50 |
| Beigene USA, Inc. | 2 | $45 |
| Gilead | 3 | $45 |
| Tempus AI, Inc | 2 | $42 |
| Sanofi | 1 | $35 |
| Incyte Corporation | 1 | $25 |
| GSK | 1 | $23 |
| AVEO Pharmaceuticals, Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Boston Scientific | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Exelixis Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,783 in reported general payments places this provider in the 35th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 92 | $1,518,676 |
| RevlimidLenalidomide | 60 | $1,041,629 |
| BrukinsaZanubrutinib | 30 | $451,046 |
| TagrissoOsimertinib Mesylate | 17 | $290,356 |
| IbrancePalbociclib | 15 | $229,630 |
| NubeqaDarolutamide | 12 | $159,635 |
| OrgovyxRelugolix | 12 | $32,537 |
| EliquisApixaban | 35 | $31,272 |
| Letrozole | 132 | $2,879 |
| Candesartan Cilexetil | 30 | $1,045 |
| Tamoxifen Citrate | 21 | $934 |
| Anastrozole | 34 | $897 |
| Imatinib Mesylate | 11 | $691 |
| Ibandronate Sodium | 48 | $638 |
| Pentoxifylline | 11 | $623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $110 | $1,809,032109 claims |
| Bristol Myers SquibbRevlimid | $67 | $1,041,62960 claims |
| Beigene USA, Inc.Brukinsa | $45 | $451,04630 claims |
| PfizerIbrance, Eliquis | $391 | $260,90150 claims |
| BayerNubeqa | $112 | $159,63512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Metairie
- Ashish UdhrainMetairie$76K
- Hana SafahBaton Rouge$2M
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Nakhle SabaBaton Rouge$842K
- Marc MatranaNew Orleans$757K
- Prakash PeddiShreveport$405K
- Sanjay JunejaBaton Rouge$346K
- Lingling duNew Orleans$173K
- Kamran ShahidLake Charles$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.